Rhumbline Advisers Revance Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 142,603 shares of RVNC stock, worth $366,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,603
Previous 135,718 5.07%
Holding current value
$366,489
Previous $348,000 5.17%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
N/A
6,885 Added 5.07%
142,603 $366,000
Q3 2024

Nov 12, 2024
SELL
$2.57 - $2.57 $1,616 - $1,616
-629 Reduced 0.46%
135,718 $348,000
Q2 2024

Aug 01, 2024
BUY
$2.34 - $4.73 $33,206 - $67,123
14,191 Added 11.62%
136,347 $350,000
Q1 2024

May 09, 2024
BUY
$4.65 - $9.31 $12,550 - $25,127
2,699 Added 2.26%
122,156 $601,000
Q4 2023

Feb 08, 2024
BUY
$5.81 - $11.2 $9,749 - $18,793
1,678 Added 1.42%
119,457 $1.05 Million
Q3 2023

Nov 09, 2023
BUY
$11.47 - $25.07 $20,106 - $43,947
1,753 Added 1.51%
117,779 $1.35 Million
Q2 2023

Aug 08, 2023
BUY
$24.7 - $37.61 $232,550 - $354,098
9,415 Added 8.83%
116,026 $2.94 Million
Q1 2023

May 11, 2023
BUY
$18.36 - $35.27 $72,723 - $139,704
3,961 Added 3.86%
106,611 $3.43 Million
Q4 2022

Feb 14, 2023
BUY
$18.32 - $30.66 $183,419 - $306,967
10,012 Added 10.81%
102,650 $1.9 Million
Q3 2022

Nov 10, 2022
BUY
$14.33 - $28.47 $131,764 - $261,781
9,195 Added 11.02%
92,638 $2.5 Million
Q2 2022

Aug 11, 2022
BUY
$11.52 - $20.4 $29,272 - $51,836
2,541 Added 3.14%
83,443 $1.15 Million
Q1 2022

May 12, 2022
SELL
$12.36 - $20.31 $9,381 - $15,415
-759 Reduced 0.93%
80,902 $1.58 Million
Q4 2021

Feb 10, 2022
SELL
$12.46 - $27.87 $47,534 - $106,324
-3,815 Reduced 4.46%
81,661 $1.33 Million
Q3 2021

Nov 12, 2021
BUY
$25.78 - $33.21 $77,675 - $100,061
3,013 Added 3.65%
85,476 $2.38 Million
Q2 2021

Aug 05, 2021
SELL
$26.8 - $31.84 $157,208 - $186,773
-5,866 Reduced 6.64%
82,463 $2.44 Million
Q1 2021

May 06, 2021
SELL
$24.03 - $29.97 $180,032 - $224,535
-7,492 Reduced 7.82%
88,329 $2.47 Million
Q4 2020

Feb 10, 2021
BUY
$23.41 - $28.34 $187,467 - $226,946
8,008 Added 9.12%
95,821 $2.72 Million
Q3 2020

Nov 12, 2020
SELL
$23.23 - $34.3 $331,073 - $488,843
-14,252 Reduced 13.96%
87,813 $2.21 Million
Q2 2020

Aug 13, 2020
BUY
$12.6 - $26.55 $259,522 - $546,850
20,597 Added 25.28%
102,065 $2.49 Million
Q1 2020

May 06, 2020
BUY
$12.46 - $27.81 $169,169 - $377,576
13,577 Added 20.0%
81,468 $1.21 Million
Q4 2019

Feb 05, 2020
BUY
$11.66 - $20.15 $14,423 - $24,925
1,237 Added 1.86%
67,891 $1.1 Million
Q3 2019

Oct 23, 2019
BUY
$10.22 - $14.5 $33,296 - $47,241
3,258 Added 5.14%
66,654 $867,000
Q2 2019

Aug 14, 2019
BUY
$10.67 - $15.49 $152,282 - $221,073
14,272 Added 29.05%
63,396 $822,000
Q1 2019

May 01, 2019
BUY
$15.4 - $20.39 $89,089 - $117,956
5,785 Added 13.35%
49,124 $774,000
Q4 2018

Jan 31, 2019
BUY
$18.06 - $24.96 $253,038 - $349,714
14,011 Added 47.77%
43,339 $872,000
Q3 2018

Nov 07, 2018
SELL
$23.55 - $30.1 $50,043 - $63,962
-2,125 Reduced 6.76%
29,328 $729,000
Q2 2018

Aug 06, 2018
BUY
$27.45 - $33.35 $200,028 - $243,021
7,287 Added 30.15%
31,453 $863,000
Q1 2018

May 02, 2018
BUY
$29.15 - $37.4 $84,243 - $108,086
2,890 Added 13.58%
24,166 $744,000
Q4 2017

Feb 09, 2018
SELL
$24.55 - $36.3 $106,227 - $157,070
-4,327 Reduced 16.9%
21,276 $761,000
Q3 2017

Nov 06, 2017
BUY
$22.55 - $28.1 $577,347 - $719,444
25,603
25,603 $705,000

Others Institutions Holding RVNC

# of Institutions
223
Shares Held
83.3M
Call Options Held
816K
Put Options Held
882K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email